23 Participants Needed

Digoxin for Medulloblastoma

Recruiting at 15 trial locations
JC
Overseen ByJessica Crimella
Age: < 65
Sex: Any
Trial Phase: Phase 2
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop taking my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications, but you cannot take medications that interfere with digoxin metabolism or any other investigational agents. It's best to discuss your current medications with the study team.

Is digoxin generally safe for humans?

Digoxin has been associated with increased risks of certain cancers, such as breast and uterus cancer, and there is a higher risk of toxicity, especially in women. However, its safety has improved over the years, and studies suggest it may be safe for some cancer patients after adjusting for other factors.12345

How is the drug digoxin unique in treating medulloblastoma?

Digoxin is unique in treating medulloblastoma because it is traditionally used for heart conditions but has shown potential antitumor effects by affecting cell growth and survival pathways, such as the NF-κB pathway, which are not typically targeted by standard cancer treatments.678910

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Research Team

JM

Jonathan Metts, MD

Principal Investigator

Moffitt Cancer Center

LM

Laura Metrock, MD

Principal Investigator

University of Alabama at Birmingham Children's of Alabama

Eligibility Criteria

This trial is for pediatric and young adult patients aged >12 months and <30 years with relapsed non-SHH, non-WNT medulloblastoma. They must have measurable disease on MRI, stable neurological status, specific cardiac criteria met, normal organ/marrow function, and a performance score of ≥50%. Prior chemotherapy and irradiation are required. Contraception use is necessary for those who can bear children.

Inclusion Criteria

My heart health meets the required standards, and I've seen a cardiologist if needed.
My neurological condition has been stable for at least 7 days.
I have recovered from surgery and been stable for over a week.
See 11 more

Exclusion Criteria

Participants unable to comply with safety monitoring requirements are ineligible
I am not currently taking any cancer treatments or experimental drugs.
I do not have serious or uncontrolled heart rhythm problems.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Digoxin will be administered orally at a standard maintenance dosing. Each cycle will be 28 days.

4 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 months

Treatment Details

Interventions

  • Digoxin
Trial Overview The study tests the effectiveness of digoxin in treating specific types of medulloblastoma that have returned after previous treatments. It focuses on patients who do not respond to standard therapies for this brain tumor affecting children and young adults.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Digoxin TreatmentExperimental Treatment1 Intervention
Digoxin will be administered orally at a standard maintenance dosing. Each cycle will be 28 days.

Digoxin is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Lanoxin for:
  • Atrial fibrillation
  • Atrial flutter
  • Supraventricular tachycardia
  • Congestive heart failure
🇺🇸
Approved in United States as Lanoxin for:
  • Atrial fibrillation
  • Atrial flutter
  • Supraventricular tachycardia
  • Congestive heart failure
🇨🇦
Approved in Canada as Lanoxin for:
  • Atrial fibrillation
  • Atrial flutter
  • Supraventricular tachycardia
  • Congestive heart failure
🇯🇵
Approved in Japan as Lanoxin for:
  • Atrial fibrillation
  • Atrial flutter
  • Supraventricular tachycardia
  • Congestive heart failure

Find a Clinic Near You

Who Is Running the Clinical Trial?

H. Lee Moffitt Cancer Center and Research Institute

Lead Sponsor

Trials
576
Recruited
145,000+

National Pediatric Cancer Foundation

Collaborator

Trials
8
Recruited
300+

Findings from Research

In a study of nearly 3 million hospital admissions in The Netherlands from 2001-2004, digoxin intoxication was found in only 0.04% of cases, indicating that such incidents are infrequent among patients receiving digoxin therapy.
Women were found to be 1.4 times more likely to experience digoxin intoxication compared to men, highlighting a gender-specific risk factor in digoxin therapy.
Age- and gender-specific incidence of hospitalisation for digoxin intoxication.Aarnoudse, AL., Dieleman, JP., Stricker, BH.[2018]

References

Age- and gender-specific incidence of hospitalisation for digoxin intoxication. [2018]
[Drug safety associated with the change of digitalis drug in Norway]. [2017]
Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. [2020]
Digoxin use after diagnosis of colorectal cancer and survival: a population-based cohort study. [2015]
Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study. [2015]
Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis. [2019]
Effects of digoxin on cell cycle, apoptosis and NF-κB pathway in Burkitt's lymphoma cells and animal model. [2019]
Breast cancer in women using digoxin: tumor characteristics and relapse risk. [2021]
Risk of cancer in patients with heart failure who use digoxin: a 10-year follow-up study and cell-based verification. [2018]
Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security